Lorenzo Antonuzzo
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)

Lorenzo Antonuzzo

Florence, IT 
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Florence, IT 
OverviewLocationsClinical Research

Overview

Lorenzo Antonuzzo practices in Florence, Italy. Mr. Antonuzzo is rated as a Distinguished expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Colorectal Cancer, Pancreatic Islet Cell Tumor, Neuroendocrine Tumor, Nephrectomy, and Cystectomy.

His clinical research consists of co-authoring 213 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 16 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Gender
Male

Locations

Florence, Italy
Other Locations
Sesto Fiorentino, Italy
Siena, Italy
Careggi, Italy
Udine, 33100, Italy
Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: Surufatinib
Study Phase: Phase 2
Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)
Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
Phase II Randomized Multicenter Study of Everolimus as Maintenance Therapy for Metastatic Neuroendocrine Carcinoma With Pulmonary or Gastroenteropancreatic Origin
Phase II Randomized Multicenter Study of Everolimus as Maintenance Therapy for Metastatic Neuroendocrine Carcinoma With Pulmonary or Gastroenteropancreatic Origin
Enrollment Status: Unknown
Publish Date: May 30, 2023
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
View 4 Less Clinical Trials

213 Total Publications

From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.
From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.
Journal: Cancer
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Antonuzzo's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile